A University of Manchester researcher has developed a treatment for
lower back pain which uses the patient’s own stem cells, sparking hopes
that it could replace the use of strong painkillers or surgery.
Low back pain (LBP) affects a large proportion of the adult population at some
point in their lives and in many of these cases it is persistent, eventually
leading to debilitating pain.
The majority of the cases of LBP are due to degeneration of the intervertebral
disc (IVD), the soft tissue which separates the vertebrae in the spine and protects
them from damage; it is the flexibility of this tissue that allows movement
of the spine (bending, twisting etc).
The IVD is comprised of a central gel-like tissue (nucleus pulposus or NP),
surrounded by a fibrous ring of tissue (annulus fibrosus or AF). Over time the
NP becomes dry and fibrous and cannot support the weight of the body, which
means the disc becomes damaged and painful and this is the source of the LBP
in many people.
Currently, treatments address the symptoms - mainly pain - using
a combination of painkillers, physiotherapy or surgery, removing tissue to relieve
the pain or fusing the vertebrae above and below the painful disc level together
to remove the pain, although this also stops movement at that disc level. None
of these options is ideal as they only treat the symptoms, not the cause, and
are of limited long-term success.
The treatment Dr Richardson is developing uses a cell-based tissue engineering
approach to regenerate the IVD at the affected level. This is achieved through
the combination of the patients’ own mesenchymal stem cells (MSCs) and
a naturally occurring collagen gel that can be implanted through a minimally-invasive
surgical technique.
MSCs are a population of progenitor cells found in the bone marrow of adults
which can differentiate into many different cell types in the body, including
bone, cartilage, fat and muscle cells. Dr Richardson found that for several
reasons he could not use cells from the IVD itself and thus spent a number of
years developing a method of producing NP cells from MSCs.
Dr Richardson explained: "Once we have extracted the bone marrow from
the patient and have purified the MSCs, they will be grown in culture and our
patented method of differentiation will be applied. They will then be embedded
within a gel which can be implanted back into the patient through an arthroscope.
The treatment has massive implications for the future of LBP treatment -
with substantial NHS cost savings as patients could be treated quickly and effectively
without any need for extended hospitalisation. In addition, as both the cause
and the symptoms are treated, only one treatment should be needed in a lifetime
and there would be no need for continuous treatments with painkillers and physiotherapy.
The patient would therefore benefit and there are also implications for productivity
in the workplace as a large number of work hours are lost every year due to
sickness leave for low back pain. In the UK alone the combined figures for lost
productivity and health-care costs due to low back pain run in the tens of millions
of pounds a year and this will only increase as the population ages.